Skye Bioscience, Inc. Net Income (Loss) Available to Common Stockholders, Diluted
Skye Bioscience, Inc. (SKYE) reported Net Income (Loss) Available to Common Stockholders, Diluted of -$10.79 million for the 3-month period ending 2026-06-30, per its 10-Q filed 2026-08-14.
Financial Statements › Income Statement › Net Income
us-gaap:NetIncomeLossAvailableToCommonStockholdersDiluted · last filed 2026-08-14
- Skye Bioscience, Inc. net income (loss) available to common stockholders, diluted for the quarter ending 2026-06-30 was -$10.79M.
- Skye Bioscience, Inc. net income (loss) available to common stockholders, diluted for the quarter ending 2026-03-31 was -$12.51M.
- Skye Bioscience, Inc. net income (loss) available to common stockholders, diluted for the quarter ending 2025-09-30 was -$12.75M.
- Skye Bioscience, Inc. net income (loss) available to common stockholders, diluted for the quarter ending 2025-06-30 was -$17.62M.
- Skye Bioscience, Inc. net income (loss) available to common stockholders, diluted for fiscal 2021 was -$8.52M.
- Skye Bioscience, Inc. net income (loss) available to common stockholders, diluted for fiscal 2020 was -$6.91M.
| Period end | Net Income (Loss) Available to Common Stockholders, Diluted 3 month | Net Income (Loss) Available to Common Stockholders, Diluted 6 month | Net Income (Loss) Available to Common Stockholders, Diluted 9 month | Net Income (Loss) Available to Common Stockholders, Diluted 12 month |
|---|---|---|---|---|
| 2026-06-30 | -$10.79M 10-Q · filed 2026-08-14 | -$23.30M 10-Q · filed 2026-08-14 | ||
| 2026-03-31 | -$12.51M 10-Q · filed 2026-05-11 | |||
| 2025-09-30 | -$12.75M 10-Q · filed 2025-11-10 | -$30.38M derived: sum of 2 quarters · filed 2026-08-14 | -$41.48M 10-Q · filed 2025-11-10 | |
| 2025-06-30 | -$17.62M 10-Q · filed 2026-08-14 | -$28.73M 10-Q · filed 2026-08-14 | ||
| 2025-03-31 | -$11.10M 10-Q · filed 2026-05-11 | |||
| 2024-09-30 | -$3.90M 10-Q · filed 2025-11-10 | -$11.80M derived: sum of 2 quarters · filed 2025-11-10 | -$16.82M 10-Q · filed 2025-11-10 | |
| 2024-06-30 | -$7.90M 10-Q · filed 2025-08-07 | -$12.92M 10-Q · filed 2025-08-07 | ||
| 2024-03-31 | -$5.02M 10-Q · filed 2025-05-08 | |||
| 2023-09-30 | -$24.95M 10-Q · filed 2024-11-07 | -$28.06M derived: sum of 2 quarters · filed 2024-11-07 | -$33.22M 10-Q · filed 2024-11-07 | |
| 2023-06-30 | -$3.11M 10-Q · filed 2024-08-09 | -$8.28M 10-Q · filed 2024-08-09 | ||
| 2023-03-31 | -$5.17M 10-Q · filed 2024-05-10 | |||
| 2022-09-30 | -$3.13M 10-Q · filed 2023-11-14 | -$6.55M derived: sum of 2 quarters · filed 2023-11-14 | -$9.59M 10-Q · filed 2023-11-14 | -$12.10M derived: sum of 4 quarters · filed 2023-11-14 |
| 2022-06-30 | -$3.42M 10-Q · filed 2022-08-15 | -$6.46M 10-Q · filed 2023-08-07 | -$8.98M derived: sum of 3 quarters · filed 2023-05-12 | -$10.68M derived: sum of 4 quarters · filed 2023-05-12 |
| 2022-03-31 | -$3.04M 10-Q · filed 2023-05-12 | -$5.56M derived: sum of 2 quarters · filed 2023-05-12 | -$7.26M derived: sum of 3 quarters · filed 2023-05-12 | -$9.29M derived: sum of 4 quarters · filed 2023-05-12 |
| 2021-12-31 | -$2.51M derived: 10-K 12 month − 10-Q 9 month · filed 2022-03-28 | -$4.22M derived: sum of 2 quarters · filed 2022-11-14 | -$6.24M derived: sum of 3 quarters · filed 2022-11-14 | -$8.52M 10-K · filed 2022-03-28 |
| 2021-09-30 | -$1.70M 10-Q · filed 2022-11-14 | -$3.73M derived: sum of 2 quarters · filed 2022-11-14 | -$6.01M 10-Q · filed 2022-11-14 | -$7.39M derived: sum of 4 quarters · filed 2022-11-14 |
| 2021-06-30 | -$2.02M 10-Q · filed 2022-08-15 | -$4.18M 10-Q · filed 2022-08-15 | -$5.69M derived: sum of 3 quarters · filed 2022-08-15 | -$7.41M derived: sum of 4 quarters · filed 2022-08-15 |
| 2021-03-31 | -$2.16M 10-Q · filed 2022-05-06 | -$3.67M derived: sum of 2 quarters · filed 2022-05-06 | -$5.39M derived: sum of 3 quarters · filed 2022-05-06 | |
| 2020-12-31 | -$1.50M derived: 10-K 12 month − 10-Q 9 month · filed 2022-03-28 | -$3.23M derived: sum of 2 quarters · filed 2022-03-28 | -$6.91M 10-K · filed 2022-03-28 | |
| 2020-09-30 | -$1.72M 10-Q · filed 2021-11-10 | -$5.40M 10-Q · filed 2021-11-10 | ||
| 2019-09-30 | -$4.93M 10-Q · filed 2020-11-06 | -$5.66M 10-Q · filed 2020-11-06 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| CalciMedica, Inc. (CALC) | United States | $0.061B | -1.42 |
| TALPHERA, INC. (TLPH) | United States | $0.060B | |
| Boundless Bio, Inc. (BOLD) | United States | $0.059B | -0.88 |
| NOMAD POWER SOLUTIONS, INC. (NMAD) | United States | $0.058B | |
| Rein Therapeutics, Inc. (RNTX) | United States | $0.063B | -1.76 |
| HYPERION DEFI, INC. (HYPD) | United States | $0.065B | |
| Annovis Bio, Inc. (ANVS) | United States | $0.056B | -1.58 |
| XBiotech Inc. (XBIT) | United States | $0.066B | -1.56 |
| HERON THERAPEUTICS, INC. /DE/ (HRTX) | United States | $0.055B | -2.38 |
| Clene Inc. (CLNN) | United States | $0.054B | -1.99 |